JP2009525764A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525764A5
JP2009525764A5 JP2008554523A JP2008554523A JP2009525764A5 JP 2009525764 A5 JP2009525764 A5 JP 2009525764A5 JP 2008554523 A JP2008554523 A JP 2008554523A JP 2008554523 A JP2008554523 A JP 2008554523A JP 2009525764 A5 JP2009525764 A5 JP 2009525764A5
Authority
JP
Japan
Prior art keywords
antibody
composition
cancer
fgf19
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008554523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525764A (ja
JP5209505B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061936 external-priority patent/WO2007136893A2/en
Publication of JP2009525764A publication Critical patent/JP2009525764A/ja
Publication of JP2009525764A5 publication Critical patent/JP2009525764A5/ja
Application granted granted Critical
Publication of JP5209505B2 publication Critical patent/JP5209505B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008554523A 2006-02-10 2007-02-09 抗ｆｇｆ１９抗体およびその使用方法 Expired - Fee Related JP5209505B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77231006P 2006-02-10 2006-02-10
US60/772,310 2006-02-10
US78060806P 2006-03-09 2006-03-09
US60/780,608 2006-03-09
US88586607P 2007-01-19 2007-01-19
US60/885,866 2007-01-19
PCT/US2007/061936 WO2007136893A2 (en) 2006-02-10 2007-02-09 Anti-fgf19 antibodies and methods using same

Publications (3)

Publication Number Publication Date
JP2009525764A JP2009525764A (ja) 2009-07-16
JP2009525764A5 true JP2009525764A5 (https=) 2010-03-18
JP5209505B2 JP5209505B2 (ja) 2013-06-12

Family

ID=38723925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554523A Expired - Fee Related JP5209505B2 (ja) 2006-02-10 2007-02-09 抗ｆｇｆ１９抗体およびその使用方法

Country Status (10)

Country Link
US (4) US7678373B2 (https=)
EP (1) EP1989230B1 (https=)
JP (1) JP5209505B2 (https=)
AR (1) AR059432A1 (https=)
AU (1) AU2007254005B2 (https=)
CA (1) CA2637988A1 (https=)
ES (1) ES2582652T3 (https=)
NZ (1) NZ569957A (https=)
TW (1) TWI388568B (https=)
WO (1) WO2007136893A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
ES2582652T3 (es) * 2006-02-10 2016-09-14 Genentech, Inc. Anticuerpos anti-FGF19 y métodos de uso de los mismos
WO2007142241A1 (ja) * 2006-06-05 2007-12-13 Hiroshima University 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
CL2008000947A1 (es) * 2007-04-02 2008-10-10 Genentech Inc Uso de un antagonista de la proteina beta-klotho (klb) para tratar trastornos asociados a la expresion o actividad de klb.
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US20090226459A1 (en) * 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
CA2722854A1 (en) * 2008-04-30 2009-11-05 Wntresearch Ab Restoration of estrogen receptor-.alpha. activity
CA2727278A1 (en) 2008-06-16 2010-01-21 Immunogen, Inc. Novel synergistic effects
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
KR101952453B1 (ko) * 2009-10-15 2019-02-26 제넨테크, 인크. 수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
CN102770456B (zh) * 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
JP4881428B2 (ja) * 2009-12-25 2012-02-22 株式会社東芝 電子機器
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
JP6211931B2 (ja) 2011-03-09 2017-10-11 セル・シグナリング・テクノロジー・インコーポレイテツド モノクローナル抗体を作製するための方法および試薬
US20140294820A1 (en) * 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
JP2015506944A (ja) * 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Ｆｇｆ１９修飾薬を使用する方法
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
TN2016000115A1 (en) 2013-10-25 2017-07-05 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
PL3082858T3 (pl) * 2013-12-20 2021-09-27 Angiobiomed Gmbh Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
RU2729161C2 (ru) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
AU2016238436A1 (en) 2015-03-25 2017-08-17 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
ES2972458T3 (es) 2016-02-10 2024-06-12 Bioinvent Int Ab Combinación de anticuerpo humano anti-FGFR4 y sorafenib
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
SG11201903911UA (en) 2016-11-02 2019-05-30 Novartis Ag Combinations of fgfr4 inhibitors and bile acid sequestrants
US20190218285A1 (en) * 2018-01-18 2019-07-18 Molecular Cloning Laboratories (MCLAB) LLC Long-Acting Therapeutic Fusion Proteins
CN109251983B (zh) * 2018-08-15 2022-03-25 深圳市罗湖区人民医院 Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
EA202191870A1 (ru) * 2019-02-02 2021-12-15 Хуахуэй Хэлс Лтд. Антитела к fgf19
EP3865155B1 (en) * 2020-02-13 2022-11-30 Orano Med Process for site-specific modification of an antibody
CN116726005B (zh) * 2022-03-03 2026-02-13 上海市第六人民医院 一种治疗运动损伤的药物及筛选方法和应用
KR20250012564A (ko) 2022-05-19 2025-01-24 타이라 바이오사이언시스, 인크. Ppar 효현제 및 fgfr4 저해제를 이용한 치료법
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020042367A1 (en) * 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20020155543A1 (en) * 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
KR20050009764A (ko) 1997-11-25 2005-01-25 제넨테크, 인크. 섬유아세포 성장 인자-19
US20050026832A1 (en) * 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1214409B1 (en) 1999-09-08 2006-05-17 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
MXPA02009224A (es) 2000-03-22 2003-03-12 Amgen Inc Moleculas similares a receptor de factor de crecimiento de fibroblastos y usos de las mismas.
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003065006A2 (en) 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
EP1553912A4 (en) * 2002-06-07 2007-08-08 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
US20050198642A1 (en) * 2004-03-04 2005-09-08 International Business Machines Corporation Mechanism for assigning home nodes to newly created threads
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
ES2582652T3 (es) 2006-02-10 2016-09-14 Genentech, Inc. Anticuerpos anti-FGF19 y métodos de uso de los mismos

Similar Documents

Publication Publication Date Title
JP2009525764A5 (https=)
JP2021524268A5 (https=)
JP2021524267A5 (https=)
TWI769537B (zh) 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途
JP2021514664A5 (https=)
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2021508469A5 (https=)
JP2021526022A5 (https=)
JP2021511058A5 (https=)
JP2010531140A5 (https=)
JP2017529838A5 (https=)
JP2010509931A5 (https=)
JP2020517249A5 (https=)
JP2010532982A5 (https=)
JP2018519364A5 (https=)
HRP20140244T1 (hr) Sastavi i metode za inhibiranje pdgfrbeta i vegf-a
JP2009545325A5 (https=)
HRP20131107T1 (hr) Anti-notch1 nrr-protutijela i postupak njihove uporabe
JP2017522861A5 (https=)
JP2008529489A5 (https=)
JP2013538553A5 (https=)
JP2017514461A5 (https=)
JP2008500815A5 (https=)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2011514150A5 (https=)